Annals of Oncology 12:29-37, 2001
© 2001 European Society for Medical Oncology
research-article |
18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma
1Departments of Oncology and Hematology University Hospital Eppendorf Hamburg, Germany
2Nuclear Medicine, University Hospital Eppendorf Hamburg, Germany
3Diagnostic Radiology, University Hospital Eppendorf Hamburg, Germany
M de Wit, MD Department of Oncology and Hematology University Hospital Eppendorf Martinistr 52 20246 Hamburg, Germany E-mail dewit{at}uke.uni-hamburg.de
PURPOSE: The value of 18FDG-PET to predict the outcome after therapy in Hodgkin's lymphoma was compared to morphologic staging and ESR
PATIENTS AND METHODS: A total of 50 concurrent 18FDG-PET and CT studies were performed in 37 patients with Hodgkin's lymphoma ESR was evaluated 32 times after treatment was completed
RESULTS: Out of 39 residual masses found by CT 8 relapses could be proven. Out of 11 CT exams with CR 3 relapses occurred. CT turned out to show a sensitivity, specificity, PPV, NPV, and accuracy of 72%, 21%, 21%, 73%, and 32%, with respect to predict disease-free survival (DFS) 18FDG-PET was positive in 22 examinations with 10 recurrences in this group Out of 28 negative 18FDG-PET 1 relapse developed 3 years later 18FDG-PET turned out to show promising sensitivity, specificity, PPV, NPV, and accuracy of 91%, 69%, 46%, 96%, 74%, with respect to predict DFS. ESR was elevated in 12 studies of which 5 relapses could be proven, while out of 20 normal ESR-studies 3 relapses occurred. Thus, ESR turned out to show sensitivity, specificity, PPV, NPV, and accuracy of 63%, 71%, 42%, 85%, and 75%, with respect to predict DFS. In summary, only 18FDG-PETwas able to predict DFS statistically significant
CONCLUSION: 18FDG-PET can be very useful in patients with residual masses after treatment
DFS, FDG-PET, Hodgkin's disease
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Markova, C. Kobe, M. Skopalova, K. Klaskova, K. Dedeckova, A. Plutschow, H. T. Eich, M. Dietlein, A. Engert, and T. Kozak FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value Ann. Onc., July 1, 2009; 20(7): 1270 - 1274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hutchings and S. F. Barrington PET/CT for Therapy Response Assessment in Lymphoma J. Nucl. Med., May 1, 2009; 50(Suppl_1): 21S - 30S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kobe, M. Dietlein, J. Franklin, J. Markova, A. Lohri, H. Amthauer, S. Klutmann, W. H. Knapp, J. M. Zijlstra, A. Bockisch, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma Blood, November 15, 2008; 112(10): 3989 - 3994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Advani, L. Maeda, P. Lavori, A. Quon, R. Hoppe, S. Breslin, S. A. Rosenberg, and S. J. Horning Impact of Positive Positron Emission Tomography on Prediction of Freedom From Progression After Stanford V Chemotherapy in Hodgkin's Disease J. Clin. Oncol., September 1, 2007; 25(25): 3902 - 3907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Juweid, S. Stroobants, O. S. Hoekstra, F. M. Mottaghy, M. Dietlein, A. Guermazi, G. A. Wiseman, L. Kostakoglu, K. Scheidhauer, A. Buck, et al. Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma J. Clin. Oncol., February 10, 2007; 25(5): 571 - 578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Guadagnolo, R. S. Punglia, K. M. Kuntz, P. M. Mauch, and A. K. Ng Cost-Effectiveness Analysis of Computerized Tomography in the Routine Follow-Up of Patients After Primary Treatment for Hodgkin's Disease J. Clin. Oncol., September 1, 2006; 24(25): 4116 - 4122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. Zinzani, M. Tani, S. Fanti, L. Alinari, G. Musuraca, E. Marchi, V. Stefoni, P. Castellucci, M. Fina, M. Farshad, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients Ann. Onc., August 1, 2006; 17(8): 1296 - 1300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Juweid Utility of Positron Emission Tomography (PET) Scanning in Managing Patients with Hodgkin Lymphoma Hematology, January 1, 2006; 2006(1): 259 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W A Weber PET for response assessment in oncology: radiotherapy and chemotherapy Br. J. Radiol., November 1, 2005; Supplement_28(1): 42 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Rohren, T. G. Turkington, and R. E. Coleman Clinical Applications of PET in Oncology Radiology, May 1, 2004; 231(2): 305 - 332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Meyer, R. F. Ambinder, and S. Stroobants Hodgkin's Lymphoma: Evolving Concepts with Implications for Practice Hematology, January 1, 2004; 2004(1): 184 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Spaepen, S. Stroobants, P. Dupont, P. Vandenberghe, J. Maertens, G. Bormans, J. Thomas, J. Balzarini, C. De Wolf-Peeters, L. Mortelmans, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation Blood, July 1, 2003; 102(1): 53 - 59. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Jerusalem, Y. Beguin, M. F. Fassotte, T. Belhocine, R. Hustinx, P. Rigo, and G. Fillet Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease Ann. Onc., January 1, 2003; 14(1): 123 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. J. Lowe and G. A. Wiseman Assessment of Lymphoma Therapy Using 18F-FDG PET J. Nucl. Med., August 1, 2002; 43(8): 1028 - 1030. [Full Text] [PDF]
|
|
|
|
|
|
M. R. Weihrauch, D. Re, K. Scheidhauer, S. Ansen, M. Dietlein, S. Bischoff, H. Bohlen, J. Wolf, H. Schicha, V. Diehl, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease Blood, November 15, 2001; 98(10): 2930 - 2934. [Abstract] [Full Text] [PDF]
|
|